Clinical Trials Logo

Perennial Allergic Rhinitis clinical trials

View clinical trials related to Perennial Allergic Rhinitis.

Filter by:

NCT ID: NCT01378429 Completed - Clinical trials for Perennial Allergic Rhinitis

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female subjects 6 to 11 years of age with a diagnosis of PAR.

NCT ID: NCT01287364 Completed - Clinical trials for Perennial Allergic Rhinitis

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Start date: February 2011
Phase: Phase 3
Study type: Interventional

This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of treatment satisfaction with and preference of an Internasal Corticosteroid (INCS)

NCT ID: NCT01270256 Completed - Clinical trials for Perennial Allergic Rhinitis

NasoNeb Delivery of an Intranasal Steroid

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

NCT ID: NCT01228630 Completed - Clinical trials for Perennial Allergic Rhinitis

Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The loratadine-pseudoephedrine combination has proven to be more effective than the use of these individual components. This prospective, randomized, double-blind and paralel study, in which patients with perennial allergic rhinitis receive one of loratadine + pseudoephedrine association drug for treatment of signs and symptoms during 4 weeks.

NCT ID: NCT01221285 Completed - Asthma Clinical Trials

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.

NCT ID: NCT01133626 Completed - Clinical trials for Perennial Allergic Rhinitis

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.

NCT ID: NCT01127620 Completed - Clinical trials for Perennial Allergic Rhinitis

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis. Open-label Phase: The objective of this extension was to evaluate the long-term safety of Bilastine 20 mg during one year in the symptomatic treatment of perennial allergic rhinitis

NCT ID: NCT01116778 Completed - Clinical trials for Perennial Allergic Rhinitis

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis

PAR
Start date: May 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of probiotics eN-Lac® capsules (Lactobacillus paracasei GMNL-32) for the treatment of children with perennial allergic rhinitis(PAR).

NCT ID: NCT01067105 Completed - Clinical trials for Perennial Allergic Rhinitis

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Start date: February 2010
Phase: Phase 3
Study type: Interventional

6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.

NCT ID: NCT01062139 Enrolling by invitation - Clinical trials for Perennial Allergic Rhinitis

Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy

Start date: October 2009
Phase: Phase 4
Study type: Interventional

Title of Study: A randomized, parallel, double-blind, multi-center, comparative study to evaluate the efficacy and safety of Cosalin monotherapy versus Cosalin and Xarlin combination therapy in patients with allergic rhinitis Objective of study: To exploratively evaluate superiority of combination therapy - twice-daily Cosalin Tab (Petasites hybridus CO2 extract) with once-daily Xarlin Tab (Levocetirizine HCl) - compared to monotherapy of Cosalin with allergic rhinitis subjects.